Updated therapeutics of asthma

Asthma is a long-term global health problem characterized by a wide range of clinical presentations. It is estimated to affect about 300 million people of all ages worldwide, causing approximately 1000 deaths per day and resulting in significant costs to healthcare systems, communities, and individuals [1]. Most of these deaths occur in low- and middle-income countries, and most of these cases are preventable [2]. The prevalence of asthma has been accompanied by a concurrent upsurge in other allergic conditions including allergic rhinitis and eczema. Patients with asthma are frequently afflicted with concomitant conditions, including but not limited to metabolic syndrome, diabetes, cardiovascular disease, osteoporosis, and psychiatric disorders. A plethora of additional morbidities have also been associated with asthma [3]. The impact of disease on individuals’ ability to engage in activities such as work, education, and family life is particularly pronounced when children are affected. A general decline in the prevalence of asthma has been observed across most age demographics over the past three decades with large geographic variations, except for school-aged children [4]. Concurrently, a decline in asthma-related mortality has also been reported, suggesting the potential improvement in the efficacy of management strategies employed to address this condition. …